Dexmethylphenidate Extended Release
@article{Moen2009DexmethylphenidateER, title={Dexmethylphenidate Extended Release}, author={Marit D. Moen and Susan J. Keam}, journal={CNS Drugs}, year={2009}, volume={23}, pages={1057-1083} }
SummaryAbstractDexmethylphenidate extended release (XR) [Focalin® XR] is a CNS stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in patients aged ≥6 years. Dexmethylphenidate contains the d-threo- enantiomer of methylphenidate. Dexmethylphenidate XR capsules have a bimodal release profile, which mimics two doses of dexmethylphenidate immediate release (IR) given 4 hours apart, and allows once-daily administration.Once-daily dexmethylphenidate XR was…
11 Citations
Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
- MedicineJournal of child and adolescent psychopharmacology
- 2008
d-MPH-ER and d,l-MPh-ER improved ADHD symptoms and were well tolerated and all active treatments provided a significant benefit over placebo at most time points to 12 hours post-dosing.
An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations
- Biology, MedicineExpert opinion on drug metabolism & toxicology
- 2019
Since there are no reliable biomarkers that can predict individualized response to long-acting stimulants, clinicians need to consider their distinctive pharmacokinetic properties, including the pharmacokinetics profile, rate and extent of absorption, variability, dose proportionality, bioequivalence and potential for accumulation.
Analytically Confirmed Intoxication by 4-Fluoromethylphenidate, an Analog of Methylphenidate.
- ChemistryJournal of analytical toxicology
- 2019
This report represents the first case of an analytically confirmed non-fatal intoxication by 4F-MPH, a halogenated derivative of methylphenidate used for the treatment of attention deficit hyperactivity disorders, which was admitted to the emergency department with neuropsychiatric and cardiologic symptoms that lasted for a week.
Risk of Serious Cardiovascular Problems with Medications for Attention-Deficit Hyperactivity Disorder
- Medicine, PsychologyCNS Drugs
- 2012
The risk for serious cardiovascular adverse events associated with stimulants, atomoxetine or α2-adrenergic agonists prescribed for ADHD is extremely low and the benefits of treating individual patients with ADHD, after an adequate assessment, outweigh the risks.
Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-threo and (±)-erythro diastereomers.
- Chemistry, BiologyDrug testing and analysis
- 2017
The identification and analytical characterization of two powdered 4F-MPH products obtained from an online vendor in 2015 suggest that the psychostimulant properties of (±)-threo-4F- MPs might be more potent in humans than MPH.
Evolution of stimulants to treat ADHD: transdermal methylphenidate
- Psychology, BiologyHuman psychopharmacology
- 2009
The following comprehensive review describes the evolution of stimulant drug formulations used in the treatment of attention‐deficit/hyperactivity disorder (ADHD). Emphasis is placed on the basic and…
Nanomedicine-based commercial formulations: current developments and future prospects
- Biology, MedicineJournal of Pharmaceutical Investigation
- 2022
An overview of currently available nanomedicine-based formulations is provided to serve as a basis for further studies regarding the use of these formulations for therapeutic purposes in near future.
Statistical Methods for Evaluating Relational Structures in Multi-Dimensional Phenotypic Data for Neuropsychiatric Disorders
- Psychology
- 2013
Author(s): Shih, Vivian H | Advisor(s): Sugar, Catherine A | Abstract: While awareness and detection of neuropsychiatric disorders have been on the rise since the mid-twentieth century, current…
The nonmedical use of prescription stimulants among dental and dental hygiene students.
- Medicine, EducationJournal of dental education
- 2011
The purpose of this study was to determine the nonmedical use of prescription attention deficit disorder (ADD) stimulant medication among dental and dental hygiene students and to help administrators and faculty members become aware of potential problems with the misuse of ADD stimulants.
Overdiagnosis of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
- Psychology, MedicineJAMA network open
- 2021
This systematic scoping review evaluates the multidecade pattern of diagnosis in attention-deficit/hyperactivity disorder in young people using a framework for identifying overdiagnosis for noncancer…
References
SHOWING 1-10 OF 56 REFERENCES
Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.
- Medicine, BiologyInternational journal of clinical pharmacology and therapeutics
- 2007
A modified release formulation with bimodal release for the pure d-enantiomer (Focalin XR) has been developed to enable a fast onset of action and a sustained activity for once-daily administration and demonstrated a bimmodal concentration-time profile.
Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder.
- Medicine, PsychologyJournal of child and adolescent psychopharmacology
- 2009
All three doses of d-MPH XR were significantly more effective than placebo in improving ADHD symptoms as confirmed by the teacher, parent and clinician and demonstrated a consistent safety profile.
Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
- Medicine, PsychologyJournal of the American Academy of Child and Adolescent Psychiatry
- 2006
Once-daily d-MPH-ER was more effective than placebo in the treatment of ADHD in children and adolescents.
A Randomized, Double-Blind, Crossover Study of Once-Daily Dexmethylphenidate in Children with Attention-Deficit Hyperactivity Disorder
- MedicineCNS drugs
- 2008
Compared with placebo, once-daily dexmethylphenidate ER 20 mg provided rapid and significant improvement at 0.5 hours post-dose in attention, deportment and academic performance, which was sustained for 8 hoursPost-dose.
Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate
- Medicine, PsychologyCNS drugs
- 2008
The switch from IR methylphenidate to OROSmethylphenidate was associated with a statistically significant improvement in all items of the SMAQ questionnaire and was more effective than IR methyl phenidate in reducing symptoms of ADHD.
Efficacy and Safety of Dexmethylphenidate Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder
- Medicine, PsychologyBiological Psychiatry
- 2007
Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
- MedicineJournal of child and adolescent psychopharmacology
- 2008
d-MPH-ER and d,l-MPh-ER improved ADHD symptoms and were well tolerated and all active treatments provided a significant benefit over placebo at most time points to 12 hours post-dosing.
Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder.
- Medicine, PsychologyJournal of child and adolescent psychopharmacology
- 2006
D-MPH-ER is safe and effective and improves classroom attention, deportment, and performance in children with ADHD and maintained significant superiority over placebo from hours 1 through 12.
Lisdexamfetamine Dimesylate
- Medicine, PsychologyCNS drugs
- 2009
Lisdexamfetamine was generally well tolerated in adult patients with ADHD, with most treatment-emergent adverse events being of mild to moderate severity and consistent with the known effects of psychostimulants.
Dose‐Proportional Pharmacokinetics of d‐threo‐Methylphenidate After a Repeated‐Action Release Dosage Form
- Medicine, ChemistryJournal of clinical pharmacology
- 2007
The pharmacokinetics of once‐daily extended‐release d‐MPH are proportional to the dose, and dose proportionality was shown for all dose‐dependent pharmacokinetic parameters.